|
End-of-day quote
New Zealand S.E.
2026-09-28
|
5-day change | 1st Jan Change | ||
| 19.36 NZD | -0.72% |
|
-2.22% | -29.91% |
| Sep. 09 | EBOS Group Declares Strike Price for Shares under Dividend Reinvestment Plan | MT |
| Aug. 19 | EBOS Group Limited Declares Final Dividend for the Year 2026, Payable on 18 September 2026 | CI |
| Market Cap | 3.23B 4.01B 2.27B 2B 1.89B 1.71B 3.22B 218B 22.6B 8.73B 111B 8.52B 8.34B 357B | P/E 2027 * |
13.8x | P/E 2028 * | 12.2x |
|---|---|---|---|---|---|
| Enterprise Value | 4.25B 5.26B 2.98B 2.62B 2.48B 2.25B 4.22B 286B 29.69B 11.47B 146B 11.19B 10.95B 469B | EV / Sales 2027 * |
0.3x | EV / Sales 2028 * | 0.29x |
| Free-Float |
90.79% | Yield 2027 * |
6.07% | Yield 2028 * | 6.58% |
| Markets | Quality | ||
|---|---|---|---|
New Zealand S.E.
| EBO | End-of-day quote | |
Australian S.E.
| EBO | Delayed | |
|
Deutsche Boerse AG
| EJG | Delayed | |
|
Boerse Muenchen
| EJG | Real-time | |
|
Börse Stuttgart
| EJG | Delayed |
Last Transcript: EBOS Group Limited
| May. 05 | EBOS : Investor Day Presentation | PU |
| Feb. 24 | EBOS : 2026 Interim Report | PU |
| Feb. 24 | EBOS : Interim Shareholders Report 2026 | PU |
| Feb. 24 | Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect | AQ |
| 25-08-26 | EBOS : 2025 Full Year Results Investor Presentation | PU |
| 1 day | -0.72% | ||
| 1 week | -2.22% | ||
| Current month | -8.25% | ||
| 1 month | -9.36% | ||
| 3 months | -6.25% | ||
| 6 months | -14.34% | ||
| Current year | -29.91% |
| 1 week | 19.15 |  | 19.74 |
| 1 month | 19.15 | | 21.5 |
| Current year | 19 | | 28.09 |
| 1 year | 19 | | 30.44 |
| 3 years | 19 | | 42.55 |
| 5 years | 19 | | 46.75 |
| 10 years | 16.05 | | 46.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Adam Hall
CEO | Chief Executive Officer | 51 | 2025-06-30 |
Alistair Gray
DFI | Director of Finance/CFO | - | 2024-09-29 |
Andrew McLean
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-04 |
| Director | Title | Age | Since |
|---|---|---|---|
Liz Coutts
CHM | Chairman | 66 | - |
| Director/Board Member | - | 2019-06-30 | |
Tracey Batten
BRD | Director/Board Member | 60 | 2021-06-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/18/26 | Buy | Director | 27 | 0.0000% | ||
| 9/18/26 | Buy | Director | 160 | 0.0001% | ||
| 9/18/26 | Buy | Director | 85 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.72% | -2.22% | -35.47% | -44.05% | 2.27B | |
| -1.19% | -3.40% | +12.59% | +93.71% | 99.84B | |
| +0.03% | -2.42% | +43.32% | +150.90% | 51.01B | |
| 0.00% | 0.00% | -14.67% | +271.01% | 20.67B | |
| -0.81% | -1.24% | -11.43% | -12.11% | 7.87B | |
| +3.68% | +0.97% | -35.25% | -36.03% | 7.06B | |
| -0.75% | +0.68% | -1.15% | +17.38% | 6.76B | |
| -1.07% | -1.93% | -19.67% | -35.07% | 5.93B | |
| -0.30% | -1.26% | -3.74% | +21.62% | 4.95B | |
| -2.45% | -5.51% | +13.72% | +16.72% | 3.99B | |
| Average | -0.46% | -0.04% | -5.17% | +44.41% | 21.03B | |
| Weighted average by Cap. | -0.83% | -1.99% | +12.63% | +105.97% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 14.03B 17.38B 9.85B 8.66B 8.19B 7.43B 13.95B 945B 98.07B 37.87B 482B 36.97B 36.17B 1,550B | 14.66B 18.16B 10.29B 9.05B 8.55B 7.76B 14.57B 987B 102B 39.56B 504B 38.62B 37.78B 1,619B |
| Net income | 229M 284M 161M 142M 134M 121M 228M 15.45B 1.6B 619M 7.88B 604M 591M 25.34B | 261M 323M 183M 161M 152M 138M 260M 17.59B 1.82B 705M 8.98B 688M 673M 28.84B |
| Net Debt | 1.01B 1.26B 711M 626M 592M 537M 1.01B 68.28B 7.08B 2.74B 34.84B 2.67B 2.61B 112B | 975M 1.21B 684M 602M 569M 516M 969M 65.66B 6.81B 2.63B 33.5B 2.57B 2.51B 108B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-28 | NZ$19.36 | -0.72% | 113,251 |
| 26-09-25 | NZ$19.50 | +0.05% | 100,774 |
| 26-09-24 | NZ$19.49 | 0.00% | 114,788 |
| 26-09-23 | NZ$19.49 | -0.86% | 534,477 |
| 26-09-22 | NZ$19.66 | -0.71% | 145,647 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EBO Stock
Select your edition
All financial news and data tailored to specific country editions
